Skip to main content

Table 2A Relative use of various endocrine agents

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

N (%)

1st line 223 (100)

2nd line 115 (100)

3rd line 71 (100)

4th line 32 (100)

5th line 8 (100)

Tamoxifen

85(38.1)

20(17.4)

5(7.0)

4(21.5)

2(25)

Anastrozole

110(49.3)

59(51.3)

12(17.0)

2(6.2)

2(25)

Exemestane

6(2.7)

24(20.9)

18(25.3)

18(56.3)

3(37.5)

Megestrol

5(2.7)

10(8.7)

35(49.3)

6(18.8)

None

Fulvestrant

17(7.6)

2(1.7)

1(1.4)

2(6.2)

None

Letrozole

None

None

None

None

1(12.5)